ArticleFrontiers in immunology2025
Liquid-liquid phase separation-driven molecular subtyping and prognostic modeling in colorectal cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liquid-liquid phase separation (LLPS) orchestrates the spatiotemporal organization of biomolecular condensates and regulates numerous biological processes. However, the extent to which dysregulated LLPS facilitates the progression of colorectal cancer (CRC) has not been elucidated. Elucidating how LLPS influences CRC possibly offers valuable insights into diagnosis and therapeutic intervention. Methods: Differentially expressed genes (DEGs) were identified from 566 CRC samples and 19 normal controls in the GSE39582 dataset. LLPS-linked genes were collected from the DrLLPS database. Prognostically significant genes were identified via univariate Cox regression, least absolute shrinkage and selection operator regression, and stepwise akaike information criterion algorithm. The risk score was derived utilizing the LLPS-linked gene signature. Patient characteristics were evaluated concerning the computed risk scores. The biological and clinical distinctions across high-risk and low-risk cohorts were further investigated, leveraging the COAD, READ, and GSE17536 validation cohorts. The expression and spatial distribution of the five prognostic genes were examined via the GSE166555 dataset and spatial transcriptomics analysis. The hydroxyacyl-coenzyme A dehydrogenase Results: A total of 430 LLPS-related DEGs were identified, from which five prognostic genes were selected to construct the LLPS-associated risk signature. Marked differences in gene expression profiles, overall prognosis, clinicopathological attributes, somatic mutations, signaling pathway activity, tumor microenvironment composition, and drug sensitivity were noted across the high-risk and low-risk populations. Furthermore, the expression of the five prognostic genes and biological functions of Conclusions: An LLPS-related prognostic model was created, enabling the stratification of the CRC population according to risk and informing individualized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.